Literature DB >> 16392028

Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease.

R A van Hogezand1, D Bänffer, A H Zwinderman, E V McCloskey, G Griffioen, N A T Hamdy.   

Abstract

INTRODUCTION: Crohn's disease is associated with a host of factors potentially increasing the risk for osteoporosis and fractures. The aim of our study was to identify the most predictive factors for skeletal pathology in this patients.
METHODS: Using a cross-sectional study design, 146 randomly selected patients with Crohn's disease of variable disease activity who were given standard therapy to control disease activity, including glucocorticoids, and who attended the outpatient clinic of the Gastroenterology Unit on regular follow-up visits were studied. Bone mineral density (BMD) measurements and lateral X-rays of the spine were performed, and biochemical parameters of bone turnover, gonadal hormones and C-reactive protein (CRP) as markers of disease activity were measured in all patients.
RESULTS: There were 61 men and 85 women, with a mean age of 43 years and mean disease duration of 20 years. The majority of patients (86%) had been treated with glucocorticoids at some stage during their illness at a median dose of 7.5 mg/day, 43% were currently using these agents and 66% had undergone an intestinal resection. Twenty-one percent of patients had below-normal 25-hydroxy vitamin D levels. Osteoporosis was documented in 26% of patients, predominantly at the femoral neck, but also at the lumbar spine or at both sites; osteopenia was documented in 45% of patients. Prevalence of vertebral and non-vertebral fractures was, respectively, 6% and 12%. Ileum resection was the most predictive factor for osteoporosis: RR 3.84 (CI 1.24-9.77, p=0.018), followed by age: RR 1.05 (CI 1.02-1.08, p<0.001) and current or past glucocorticoid use: RR 1.94 (CI 0.92-4.10, p=0.08).
CONCLUSION: Our data suggest that in patients with Crohn's disease, the risk of osteoporosis is best predicted by a history of ileum resection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16392028     DOI: 10.1007/s00198-005-0016-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  48 in total

1.  Osteoporosis in inflammatory bowel disease.

Authors:  J Compston
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Medical treatment of Crohn's disease.

Authors:  Janet Harrison; Stephen B Hanauer
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

3.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.

Authors:  P Vestergaard; K Krogh; L Rejnmark; S Laurberg; L Mosekilde
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 4.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

5.  Bone mineral density and nutritional status in children with chronic inflammatory bowel disease.

Authors:  A M Boot; J Bouquet; E P Krenning; S M de Muinck Keizer-Schrama
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

6.  Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.

Authors:  C N Bernstein; L L Seeger; J W Sayre; P A Anton; L Artinian; F Shanahan
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Longitudinal study of cortical bone loss in patients with inflammatory bowel disease.

Authors:  D Clements; R J Motley; W D Evans; A D Harries; J Rhodes; R J Coles; J E Compston
Journal:  Scand J Gastroenterol       Date:  1992-12       Impact factor: 2.423

9.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.

Authors:  T P Van Staa; L Abenhaim; C Cooper; B Zhang; H G Leufkens
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-09       Impact factor: 2.890

10.  The association between corticosteroid use and development of fractures among IBD patients in a population-based database.

Authors:  Charles N Bernstein; James F Blanchard; Colleen Metge; Marina Yogendran
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

View more
  8 in total

1.  Conditional Gata4 deletion in mice induces bile acid absorption in the proximal small intestine.

Authors:  Eva Beuling; Ilona M Kerkhof; Grace A Nicksa; Michael J Giuffrida; Jamie Haywood; Daniel J aan de Kerk; Christina M Piaseckyj; William T Pu; Terry L Buchmiller; Paul A Dawson; Stephen D Krasinski
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

2.  Prediction of low bone mineral density in patients with inflammatory bowel diseases.

Authors:  Solvey Schüle; Jean-Benoît Rossel; Diana Frey; Luc Biedermann; Michael Scharl; Jonas Zeitz; Natália Freitas-Queiroz; Valérie Pittet; Stephan R Vavricka; Gerhard Rogler; Benjamin Misselwitz
Journal:  United European Gastroenterol J       Date:  2016-06-30       Impact factor: 4.623

Review 3.  Clinical relevance of changes in bone metabolism in inflammatory bowel disease.

Authors:  Pal Miheller; Katalin Lorinczy; Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

4.  High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients.

Authors:  Judith Haschka; Simon Hirschmann; Arnd Kleyer; Matthias Englbrecht; Francesca Faustini; David Simon; Camille P Figueiredo; Louis Schuster; Christian Muschitz; Roland Kocijan; Heinrich Resch; Raja Atreya; Jürgen Rech; Markus F Neurath; Georg Schett
Journal:  J Crohns Colitis       Date:  2016-01-27       Impact factor: 9.071

5.  Frequency of low bone mineral density in Saudi patients with inflammatory bowel disease.

Authors:  Mona H Ismail; Abdulmohsen H Al-Elq; Mahdi E Al-Jarodi; Nahla A Azzam; Abdulrahman M Aljebreen; Sami A Al-Momen; Bahaa F Bseiso; Fatma A Al-Mulhim; Abdulaziz Alquorain
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

Review 6.  Manipulating bone disease in inflammatory bowel disease patients.

Authors:  Pal Miheller; William Gesztes; Peter L Lakatos
Journal:  Ann Gastroenterol       Date:  2013

7.  Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.

Authors:  Solvey Schüle; Jean-Benoît Rossel; Diana Frey; Luc Biedermann; Michael Scharl; Jonas Zeitz; Natália Freitas-Queiroz; Thomas Kuntzen; Thomas Greuter; Stephan R Vavricka; Gerhard Rogler; Benjamin Misselwitz
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 8.  Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.

Authors:  Yaqot N Baban; Christopher M Edicheria; Joseph Joseph; Parneet Kaur; Jihan A Mostafa
Journal:  Cureus       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.